SWOG clinical trial number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

12% Accrual
Accrual
12%
Open
Phase
12% Accrual
Accrual
12%
Abbreviated Title
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Status Notes
Effective October 29th, 2024, at 12:00 p.m. Pacific, Arm 3 will temporarily close to accrual.

Effective June 13, 2024, at 12:00 a.m. Pacific, Arm 1 will temporarily close to accrual.
Activated
06/30/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Tazemetostat Lenalidomide Tafasitamab Zanubrutinib

Other Clinical Trials

S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
14% Accrual
Accrual
14%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number